| Abstract: | The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof. |
|
Patent landscape, scope, and claims: |
US Patent 11,066,358 scope and claims: Form IV crystalline composition of PF-00191189 dimer impurity controls
US Patent 11,066,358 is tightly drafted around a single, specific crystalline solid form: Form IV of the active ingredient N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide (PF-00191189). The claim set is narrow by design and adds enforceability hooks through (i) solid-state characterization constraints (XRPD/DSC stability), (ii) quantitative control of a specific impurity (PF-00191189 dimer), and (iii) downstream product claims limited to oral dosage forms (tablet/capsule).
Below is a structured claim-by-claim scope map and a practical landscape view of what competitors can and cannot design around in the US.
What does claim 1 of US 11,066,358 cover: “Form IV” crystalline composition of PF-00191189?
Claim 1 is an independent product claim. It covers:
- A crystalline composition
- that is essentially pure Form IV
- of the specific chemical entity defined as:
N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide
(Formula I).
- The phrase “essentially pure” functions as a functional purity boundary that typically permits limited non-Form-IV content while requiring that the material be predominantly Form IV.
Scope implications for infringement design
- Solid form control is the primary gate. Even if the chemical identity matches Formula I, using a different polymorph/solvate form avoids claim 1 unless the accused material still meets the “essentially pure Form IV” requirement.
- “Essentially pure Form IV” is not just nomenclature. It implies a measured solid-state phase distribution consistent with Form IV and characterized by the patent’s definition of Form IV (typically via XRPD and/or DSC thresholds in the specification, even though those thresholds are not recited in claim 1).
- Because claim 1 does not recite particle size, morphology, excipient content, or manufacturing conditions, those parameters are likely irrelevant to claim 1 unless they affect whether the material qualifies as “Form IV.”
When is claim 2 triggered: does XRPD/DSC stability for 3 months narrow enforceability?
Claim 2 depends on claim 1 and adds a storage-performance limitation:
- The crystalline composition has an XRPD pattern and/or DSC profile that is substantially unchanged after storage for 3 months
- under standard warehouse conditions:
- 15°C to 25°C
- ≤65% relative humidity
Scope implications
- This is a form stability limitation. It can tighten infringement proof by requiring that the tested material maintains Form IV as characterized by XRPD and/or DSC after the specified stress/storage period.
- It does not require a specific storage container, light exposure, agitation, or formulation context. The limitation is anchored to time and environmental conditions.
Design-around strategy signal
- A generic/crystallization competitor trying to avoid claim 2 while still approaching claim 1 could aim for:
- a material that is Form IV but whose solid-state signature changes under the cited conditions; or
- a material that passes characterization at release but does not remain “substantially unchanged” over 3 months.
- Claim 1 still remains a risk even if claim 2 is avoided, because claim 2 is dependent.
What do claims 3–5 cover: impurity PF-00191189 dimer content thresholds
Claims 3–5 depend from claim 1 and add a quantitative impurity specification for dimeric impurity PF-00191189.
Claim 3 (broad impurity constraint)
- Crystalline composition contains ≤0.2% by weight of dimeric impurity PF-00191189.
Claim 4 (middle band)
- Crystalline composition contains about 0.05% to about 0.19% by weight of dimeric impurity PF-00191189.
Claim 5 (zero-detect band)
- Crystalline composition contains no detectable amount of dimeric impurity PF-00191189.
Scope implications
- These are chemistry and QC-defined boundaries, not just “purity” in the abstract.
- “No detectable amount” is measurement-method dependent. The claim language implies a detection limit, which is typically supplied in the specification or controlled by the testing method used in enforcement.
- Claim 4’s numeric band overlaps with claim 3’s limit. Claim 4 narrows to a sub-range; it may serve evidentiary coverage when accused product falls into that middle region.
Practical enforcement advantage
- If a competitor uses a Form IV material that contains dimer impurity above 0.2%, they can avoid claims 3–5. But claim 1 still targets “essentially pure Form IV” without a dimer cap, so they may remain exposed to claim 1 depending on what “essentially pure” means relative to impurity content and whether dimer is present as a non-Form-IV constituent.
- If the patent’s definition of “essentially pure” in the specification ties to impurity tolerances or phase purity, the dimer constraint can indirectly feed back into claim 1’s meaning.
What is the downstream product coverage: claim 6 pharmaceutical composition for the crystalline composition
Claim 6 depends on claim 1 and covers:
- A pharmaceutical composition
- comprising the crystalline composition of claim 1
- plus a pharmaceutically acceptable carrier
Scope implications
- This is a straightforward formulation claim. It is not limited to specific carriers, unit dose geometry, release profiles, or coatings.
- It can capture both immediate-release and modified-release products unless those are excluded by the specification or by how “pharmaceutical composition” is construed.
How far do claims 7–10 narrow: oral and dosage form limitations (tablet/capsule)
Claim 7
- pharmaceutical composition is for oral administration
Claim 8
- pharmaceutical composition is a tablet or capsule
Claim 9
- pharmaceutical composition is a tablet
Claim 10
- pharmaceutical composition is a capsule
Scope implications
- These dependent claims create multiple enforcement hooks that track the most common generic dosage formats.
- If a competitor launches as a different oral dosage form (e.g., oral film) the tablet/capsule dependent claims may not be met, but claim 6 and claim 7 could still be at issue depending on how strictly the dosage form is limited in the independent claim chain.
How broad is US 11,066,358 in the solid-state space: what it does and does not cover
What it covers (high-confidence)
- Only the defined active ingredient scaffold in Form IV crystalline form.
- Essentially pure Form IV compositions.
- Form IV solids with:
- stability signature constraints after 3 months
- and/or specific dimer impurity ranges/limits.
- Formulations containing the Form IV solid and suitable oral carriers, including tablets and capsules.
What it does not appear to cover from the provided claims
- Other polymorphs (Form I/II/III/other forms).
- Other impurities unless they are tied to “essentially pure” in the specification.
- Non-crystalline forms (amorphous dispersion) unless they still qualify as “crystalline composition.”
- Process claims are not provided in the user text; this is a product-centric estate.
- Methods of use are not included in the provided claims.
Which generic entry risks exist for Form IV crystallines in the US
Risk profile by design choice
- Generic uses Form IV solids that match the characterization and impurity limits
- High risk across claim 1 and claim 6, with additional risk under claims 2–5 depending on stability and dimer impurity testing results.
- Generic uses Form IV but exceeds dimer impurity cap
- Potentially avoids claims 3–5, but claim 1 and claim 6 exposure remains if the material is still “essentially pure Form IV.”
- Generic switches to another solid form
- Likely avoids claim 1 and claim 6, but may face other forms’ patents if present in the estate.
- Generic uses Form IV but compromises stability under warehouse conditions
- Can potentially avoid claim 2 while remaining exposed under claim 1 and claim 6.
What does the claim structure imply about patent “scope boundaries” in litigation
- The independent claims are composition-centric with strong identification by (i) identity of the API (Formula I) and (ii) specific solid form (Form IV).
- The dependent claims provide objective, testable parameters:
- XRPD/DSC stability after a defined period and conditions
- measured weight % of a defined impurity
- This is a litigation-ready structure for chemical companies: it reduces reliance on subjective interpretation and shifts disputes toward:
- whether the accused solid is “Form IV” under the patent’s characterization definition
- whether the measured dimer impurity level and detection result falls inside the numeric ranges
How does the patent likely compare with typical crystalline-form estates: key differentiators
Compared with broader crystalline patents that cover multiple polymorphs or broader impurities, US 11,066,358 appears:
- Narrow in form identity (single named form: Form IV)
- Narrow in impurity identity (specific “dimeric impurity PF-00191189” only)
- Broad in formulation carriers (claim 6 does not limit excipients beyond “pharmaceutically acceptable carrier”)
- Narrow in dosage forms via dependent claims (tablet/capsule)
This profile usually makes the case more about analytical equivalence (XRPD/DSC and impurity testing) than about broad medicinal chemistry claim interpretation.
Key takeaways
- Claim 1 is the core: a crystalline, essentially pure Form IV of the specified PF-00191189 benzamide scaffold.
- Claims 2 and 3–5 add objective proof points: Form IV must show XRPD/DSC stability after 3 months and/or satisfy dimeric impurity PF-00191189 limits of ≤0.2 wt%, ~0.05–0.19 wt%, or no detectable amount.
- Claim 6 extends to products: any pharmaceutical composition with the claim 1 Form IV solid and an acceptable carrier.
- Claims 7–10 narrow to oral unit doses: oral use, then tablet and capsule subtypes.
- Primary generic design-around lever: use a different solid form or ensure the material does not meet the Form IV identity and/or dimer impurity thresholds.
FAQs
1) Does US 11,066,358 cover amorphous PF-00191189?
The provided claims target a “crystalline composition” of essentially pure Form IV, so an amorphous form would not fit the claim language if it is not crystalline Form IV.
2) Can a generic avoid all claims by raising the dimer impurity above 0.2 wt%?
Claims 3–5 would be avoided, but claims 1 and 6 could still apply because they do not recite the dimer impurity limit in the text provided.
3) If a product is Form IV at release but not after 3 months, which claims are implicated?
It may reduce exposure under claim 2 specifically, while exposure under claim 1 and claim 6 remains if the material is still “essentially pure Form IV” at the relevant time.
4) Are tablet and capsule the only covered dosage forms?
Claims 8–10 are tablet/capsule dependent limitations. Claim 6 is broader than tablet/capsule and only requires a pharmaceutically acceptable carrier; claim 7 requires oral administration.
5) What testing drives infringement arguments under these claims?
The claim set emphasizes XRPD and DSC (for identity and stability) and quantitative impurity assays for dimeric impurity PF-00191189.
References
- US Patent 11,066,358.
More… ↓
⤷ Start Trial
|
